Toggle Main Menu Toggle Search

Open Access padlockePrints

Dose related growth response to indometacin(star) in Gitelman syndrome

Lookup NU author(s): Dr Malcolm Coulthard


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Growth failure is a recognised feature of Gitelman syndrome, although it is not as frequent as in Bartter syndrome. Indometacin is reported to improve growth in Bartter syndrome, hut not in Gitelman syndrome, where magnesium supplements are recommended. This paper presents 3 sisters with Gitelman syndrome who could not tolerate magnesium supplements, and whose hypotension and polyuria were eliminated by taking 2 mg/kg/day indometacin, bur who grew poorly. However, increasing the indometacin dose to 4 mg/kg/day improved their growth significantly, without changing their symptoms or biochemistry. Gastrointestinal haemorrhage necessitated the use of misoprostol.

Publication metadata

Author(s): Liaw LCT, Banerjee K, Coulthard MG

Publication type: Article

Publication status: Published

Journal: Archives of Disease in Childhood

Year: 1999

Volume: 81

Issue: 6

Pages: 508-510

Print publication date: 01/12/1999

ISSN (print): 0003-9888

ISSN (electronic): 1468-2044

Publisher: BMJ Group


DOI: 10.1136/adc.81.6.508


Altmetrics provided by Altmetric